Compare Nu Holdings Ltd (NU) vs Pfizer Inc (PFE) Price & Performance

NU Holdings stock trades at $15.33, down 0.26% today, with a bullish technical outlook and strong fundamental growth. The company reported record Q2 2026 results with $1 billion net income and 39% revenue growth year-over-year, driven by expanding customer base and AI integration. Analyst consensus is a Buy with a $17.20 price target, reflecting confidence in sustained profitability and market expansion in Brazil and Mexico.

The stock presents a compelling growth opportunity with robust earnings momentum and positive sentiment, though risks include credit quality concerns and competitive pressures. Upside potential exists if execution continues, but investors should monitor loan performance and macroeconomic factors in key markets.

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.